[go: up one dir, main page]

CN113698357A - 磺胺嘧啶类衍生物及其在抗肿瘤药物的应用 - Google Patents

磺胺嘧啶类衍生物及其在抗肿瘤药物的应用 Download PDF

Info

Publication number
CN113698357A
CN113698357A CN202111150453.9A CN202111150453A CN113698357A CN 113698357 A CN113698357 A CN 113698357A CN 202111150453 A CN202111150453 A CN 202111150453A CN 113698357 A CN113698357 A CN 113698357A
Authority
CN
China
Prior art keywords
sulfadiazine
derivative
antitumor drugs
application
400mhz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202111150453.9A
Other languages
English (en)
Inventor
杨金飞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Conservation Xiamen Medical Technology Co ltd
Original Assignee
Conservation Xiamen Medical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conservation Xiamen Medical Technology Co ltd filed Critical Conservation Xiamen Medical Technology Co ltd
Priority to CN202111150453.9A priority Critical patent/CN113698357A/zh
Publication of CN113698357A publication Critical patent/CN113698357A/zh
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明属于药物化学技术领域，尤其涉及磺胺嘧啶类衍生物和制备方法，及其作为PD1/PDL1抑制剂在抗肿瘤药物中的应用。本发明的提供一种通式(I)所示的新型磺胺嘧啶类衍生物，及其几何异构体或其药学上可接受的盐、水合物、溶剂化物或前药。本发明通过实验显示，本课题组合成的新型磺胺嘧啶类衍生物具有开发抗肿瘤药物的前景。

Description

磺胺嘧啶类衍生物及其在抗肿瘤药物的应用
技术领域
本发明属于药物化学技术领域，尤其涉及磺胺嘧啶类衍生物和制备方法，及其作为PD1/PD-L1抑制剂在抗肿瘤药物中的应用。
背景技术
据统计，肺癌是世界范围内癌症死亡的主要原因，因为它的存活率很低。非小细胞肺癌占肺癌的85％，肺腺癌是NSCLC最常见的组织学类型。传统的治疗方法对患者的选择仍然有限，最近，免疫疗法因其卓越的疗效而出现并流行起来。PD1/PDL1免疫检查点抑制剂已被开发并应用于非小细胞肺癌的治疗。PD1由活化的T细胞、B淋巴细胞和自然杀伤细胞表达，PDL1为PD1配体。PDL1在局部肿瘤环境中由T淋巴细胞、上皮细胞、内皮细胞、肿瘤细胞和其他细胞表达。PD1和PDL1相互作用抑制T细胞活化并帮助肿瘤细胞逃避免疫监视。
目前，已被用于治疗NSCLC的PD1/PD-L1免疫检查点抑制剂包括nivolumab、pembrolizumab、atezolizumab和duvalumab。一项研究显示，与传统化疗相比，pembrolizumab单抗作为一线疗法显著提高了局部晚期或转移性非小细胞肺癌的总存活率，当PDL1TPS≥为1％时，不会使表皮生长因子受体或碱性磷酸酶的改变变得敏感。Pembrolizumab单抗治疗无驱动基因突变、PDL1高表达的非小细胞肺癌患者目前被推荐为一线治疗方案。
综上所述，研究新型的特异性更强的PD1/PD-L1抑制剂，对肿瘤药物患者的临床免疫治疗意义重大。
发明内容
本发明针对现有技术的不足，提供一种磺胺嘧啶类衍生物；以及该衍生物的制备方法和其作为PD1/PD-L1抑制剂在抗肿瘤免疫治疗药物中的应用。
为实现上述目的，本发明采取的技术方案是：本发明的提供一种通式(I)所示的磺胺嘧啶类衍生物，及其几何异构体或其药学上可接受的盐、水合物、溶剂化物或前药；
Figure BDA0003286845780000021
所述R1或R2选自氢、卤素、C1-C6烷氧基、C1-C6烷基、C1-C6环烷基、烯烃基、炔烃基或芳香基。
所述R3选自氢、C1-C6烷氧基、C1-C6烷基中单个或多个取代。
本发明通式(I)所示的磺胺嘧啶类衍生物类衍生物，选自：
Figure BDA0003286845780000022
本发明所述的“烷基”是指直链或支链的烷基，其中C1-C6基团是指该部分中具有1-6个碳原子，即基团包含1、2、3、4、5或6个碳原子。
本发明所述的“烷氧基”是指烷基醚基烷基，例如甲氧基、乙氧基、正丙氧基、异丙氧基、正丁氧基、异丁氧基、仲丁氧基和叔丁氧基等。
本发明所述的“卤素”是指氟、氯、溴或碘。
按照本发明的式I化合物，均可按照路线1的方法进行合成，由相应的起始原料4-取代苯基苯甲醛与取代的磺胺嘧啶发生还原胺化反应得到目标化合物。合成路线1如下。
Figure BDA0003286845780000031
本发明所述的磺胺嘧啶类衍生物可以作为PD1/PD-L1抑制剂，作为肿瘤患者的临床免疫治疗药物。
具体实施方式
下述实施例旨在阐述而不是限制本发明的范围。化合物的核磁共振氢谱用BrukerARX-400测定，质谱用Agilent 1100 LC/MS测定；所用试剂均为分析纯或化学纯。
实施例1。
Figure BDA0003286845780000032
将4-苯基苯甲醛(0.50g,2.74mmol)和磺胺间甲氧嘧啶(0.77g,2.74mmol)溶于1,2-二氯乙烷中，然后分批加入醋酸硼氢化钠(2.33g,10.98mmol)，继续室温反应24h，TLC检测反应完成。加入40mL水，30mL二氯甲烷萃取，饱和食盐水洗涤有机层，Na2SO4干燥过夜。滤除干燥剂，减压蒸除溶剂，残余物经硅胶柱层析纯化，得0.67g，收率54.68％。
1H-NMR(400MHz,DMSO-d6)δ11.36(s,1H),8.39(s,1H),7.74(d,J＝7.3Hz,2H),7.64(d,J＝8.8Hz,2H),7.49–7.45(m,4H),7.43-7.40(m,3H),7.31(s,1H),7.14(d,J＝8.4Hz,2H),6.30(s,1H),4.32(s,2H),3.80(s,3H).ESI-MS m/z:447.1[M+H]+.
实施例2。
Figure BDA0003286845780000041
1H-NMR(400MHz,DMSO-d6)δ11.34(s,1H),8.38(s,1H),7.62(d,J＝8.4Hz,2H),7.52–7.49(m,4H),7.41(d,J＝8.2Hz,2H),7.31(s,1H),7.14-7.11(d,J＝8.4Hz,4H),6.31(s,1H),4.31(s,2H),3.81(s,3H).ESI-MS m/z:465.1[M+H]+.
实施例3。
Figure BDA0003286845780000042
1H-NMR(400MHz,DMSO-d6)δ11.34(s,1H),8.39(s,1H),7.74-7.70(m,2H),7.64(d,J＝8.8Hz,2H),7.49-7.46(m,3H),7.41(d,J＝8.2Hz,2H),7.31-7.27(m,2H),7.12(d,J＝8.0Hz,2H),6.29(s,1H),4.30(s,2H),3.82(s,3H).ESI-MS m/z:465.1[M+H]+.
实施例4。
Figure BDA0003286845780000051
1H-NMR(400MHz,DMSO-d6)δ11.38(s,1H),8.39(s,1H),7.78(d,J＝7.8Hz,2H),7.64(d,J＝8.8Hz,2H),7.50–7.46(m,4H),7.41(t,J＝7.0Hz,1H),7.31(s,1H),7.24(t,J＝7.6Hz,1H),7.16-7.14(m,3H),6.31(s,1H),4.30(s,2H),3.82(s,3H).ESI-MS m/z:465.1[M+H]+.
实施例5。
Figure BDA0003286845780000052
1H-NMR(400MHz,DMSO-d6)δ11.35(s,1H),8.38(s,1H),7.62(d,J＝8.4Hz,2H),7.47(d,J＝7.8Hz,2H),7.40(d,J＝7.6Hz,2H),7.33-7.31(m,3H),7.17-7.14(m,4H),6.32(s,1H),4.33(s,2H),3.78(s,3H),2.35(s,3H).ESI-MS m/z:461.1[M+H]+.
实施例6。
Figure BDA0003286845780000053
1H-NMR(400MHz,DMSO-d6)δ11.34(s,1H),8.36(s,1H),7.70-7.65(m,3H),7.46(d,J＝7.4Hz,2H),7.42-7.39(m,3H),7.34-7.31(m,3H),7.15(d,J＝8.6Hz,2H),6.30(s,1H),4.30(s,2H),3.81(s,3H),2.24(s,3H).ESI-MS m/z:461.1[M+H]+.
实施例7。
Figure BDA0003286845780000061
1H-NMR(400MHz,DMSO-d6)δ11.35(s,1H),8.39(s,1H),8.06(d,J＝8.4Hz,2H),7.64–7.60(m,4H),7.48(d,J＝8.0Hz,2H),7.40(d,J＝7.8Hz,2H),7.31(s,1H),7.14(d,J＝8.2Hz,2H),6.31(s,1H),4.30(s,2H),3.78(s,3H).ESI-MS m/z:481.1[M+H]+.
实施例8。
Figure BDA0003286845780000062
1H-NMR(400MHz,DMSO-d6)δ11.36(s,1H),8.38(s,1H),7.92(s,1H),7.67-7.64(m,3H),7.56(d,J＝7.4Hz,2H),7.46(d,J＝8.2Hz,2H),7.41(d,J＝7.6Hz,2H),7.31(s,1H),7.12(d,J＝8.0Hz,2H),6.31(s,1H),4.31(s,2H),3.78(s,3H).ESI-MS m/z:516.1[M+H]+.
实施例9。
Figure BDA0003286845780000063
1H-NMR(400MHz,DMSO-d6)δ11.34(s,1H),8.40(s,1H),7.64(d,J＝8.6Hz,2H),7.54(d,J＝8.0Hz,2H),7.47(d,J＝7.8Hz,2H),7.42(d,J＝7.4Hz,2H),7.31(s,1H),7.12(d,J＝8.2Hz,2H),6.88(d,J＝8.0Hz,2H),6.30(s,1H),4.33(s,2H),3.81(s,6H).ESI-MS m/z:477.2[M+H]+.
实施例10。
Figure BDA0003286845780000071
1H-NMR(400MHz,DMSO-d6)δ11.16(s,1H),7.66(d,J＝8.6Hz,2H),7.53–7.48(m,4H),7.42(d,J＝8.0Hz,2H),7.32(s,1H),7.14-7.10(d,J＝8.4Hz,4H),6.36(s,1H),4.32(s,2H),2.44(s,3H),2.38(s,3H).ESI-MS m/z:463.1[M+H]+.
实施例11。
Figure BDA0003286845780000072
1H-NMR(400MHz,DMSO-d6)δ11.44(s,1H),7.68(d,J＝8.2Hz,2H),7.54(d,J＝7.8Hz,2H),7.48(d,J＝7.6Hz,2H),7.43(d,J＝7.6Hz,2H),7.35(s,1H),7.14(d,J＝8.0Hz,2H),6.92(d,J＝8.2Hz,2H),6.02(s,1H),4.33(s,2H),3.81(s,6H),3.76(s,3H).ESI-MS m/z:507.1[M+H]+.
一、HTRF均相时间分辨荧光技术。
测试原理：Cisbio公司开发的HTRF PD-1/PD-L1 binding assay kit试剂盒，PD-1/PD-L1结合测定旨在测量PD-1和PD-L1蛋白之间的相互作用。通过使用抗Tag1-Europium(HTRF供体)和抗Tag2-XL665(HTRF受体)来检测Tag1-PD-L1和Tag2-PD-1之间的相互作用。当供体抗体和受体抗体由于PD-L1和PD-1的的紧密结合而接近时，供体抗体的激发引发朝向受体抗体的荧光共振能量转移((FRET)，后者又在665nm处特异性发射。该特定信号与PD-1/PD-L1相互作用的程度成正比。因此阻断PD-1/PD-L1相互作用的化合物将导致HTRF信号的减弱。
测试方法：按照说明书操作，对本发明所述的化合物测试对PD-1/PD-L1的抑制效果。在384孔板中预设给药组、对照组和阴性对照组，每组三个复孔。依次向每孔中加入4μLTag1-PD-L1工作液、4μL Tag1-PD-1工作液，并吹打均匀；接着向每孔中加入2μL的化合物稀释液，混合均匀室温孵育15min后，向每孔中依次加入Anti-Tag1-Europium和Anti-Tag2-XL665，封膜避光孵育2小时，使用Tecan酶标仪读取荧光值(Ex:320nM；Em:620和665nM)，然后计算抑制率及拟合IC50，见表1。
表1化合物测试对PD-1/PD-L1的抑制活性(IC50)。
实施例 IC<sub>50</sub>(μM)
实施例1 6.8
实施例2 4.7
实施例3 0.28
实施例4 0.64
实施例5 12.5
实施例6 8.9
实施例7 1.6
实施例8 0.47
实施例9 24.6
实施例10 10.6
实施例11 31.5
采用HTRF(均相时间分辨荧光)技术标准操作程序测定本发明所述的一种磺胺嘧啶类衍生物对PD-1/PD-L1的抑制效果，结果显示该化合物对PD-1/PD-L1具有*明显的抑制作用。

Claims (3)

1.磺胺嘧啶类衍生物，其特征在于，所述的衍生物结构式如下：
Figure FDA0003286845770000011
其中，所述R1或R2选自氢、卤素、C1-C6烷氧基、C1-C6烷基、C1-C6环烷基、烯烃基、炔烃基或芳香基；
所述R3选自氢、C1-C6烷氧基、C1-C6烷基中单个或多个取代。
2.如权利要求1所述的磺胺嘧啶类衍生物，其特征在于，所述的衍生物选自：
Figure FDA0003286845770000012
3.如权利要求1-2任一所述的磺胺嘧啶类衍生物作为抑制剂，作为肿瘤患者的临床免疫治疗药物。
CN202111150453.9A 2021-09-29 2021-09-29 磺胺嘧啶类衍生物及其在抗肿瘤药物的应用 Withdrawn CN113698357A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111150453.9A CN113698357A (zh) 2021-09-29 2021-09-29 磺胺嘧啶类衍生物及其在抗肿瘤药物的应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111150453.9A CN113698357A (zh) 2021-09-29 2021-09-29 磺胺嘧啶类衍生物及其在抗肿瘤药物的应用

Publications (1)

Publication Number Publication Date
CN113698357A true CN113698357A (zh) 2021-11-26

Family

ID=78662298

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111150453.9A Withdrawn CN113698357A (zh) 2021-09-29 2021-09-29 磺胺嘧啶类衍生物及其在抗肿瘤药物的应用

Country Status (1)

Country Link
CN (1) CN113698357A (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009129267A2 (en) * 2008-04-14 2009-10-22 The Board Of Regents Of The University Of Texas System Small molecule inhibitors of the pleckstrin homology domain and methods for using same
CN103664878A (zh) * 2012-09-12 2014-03-26 山东亨利医药科技有限责任公司 杂芳环及其衍生物类酪氨酸激酶抑制剂
WO2015054662A1 (en) * 2013-10-10 2015-04-16 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives as 12-lipoxygenase inhibitors
WO2016210296A1 (en) * 2015-06-26 2016-12-29 Dana-Farber Cancer Institute, Inc. 4,6-pyrimidinylene derivatives and uses thereof
CN110325531A (zh) * 2016-12-09 2019-10-11 泽农医药公司 苯磺酰胺及其作为治疗剂的用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009129267A2 (en) * 2008-04-14 2009-10-22 The Board Of Regents Of The University Of Texas System Small molecule inhibitors of the pleckstrin homology domain and methods for using same
CN103664878A (zh) * 2012-09-12 2014-03-26 山东亨利医药科技有限责任公司 杂芳环及其衍生物类酪氨酸激酶抑制剂
WO2015054662A1 (en) * 2013-10-10 2015-04-16 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives as 12-lipoxygenase inhibitors
WO2016210296A1 (en) * 2015-06-26 2016-12-29 Dana-Farber Cancer Institute, Inc. 4,6-pyrimidinylene derivatives and uses thereof
CN110325531A (zh) * 2016-12-09 2019-10-11 泽农医药公司 苯磺酰胺及其作为治疗剂的用途

Similar Documents

Publication Publication Date Title
Wee et al. Synthesis and evaluation of functionalized isoindigos as antiproliferative agents
Ma et al. Virtual screening and optimization of Type II inhibitors of JAK2 from a natural product library
CN103054869A (zh) 含三唑基的氨基二硫代甲酸酯化合物在制备以lsd1为靶标药物中的应用
EP4127209A2 (en) Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer
Zhang et al. Synthesis and anticancer activities of 4-(4-substituted piperazin)-5, 6, 7-trialkoxy quinazoline derivatives
CN107929276A (zh) 一种紫杉醇和cdks激酶抑制剂联合用药物组合物
WO2022166994A1 (zh) 一种萘基脲类化合物、其制备方法及应用
CN103664908A (zh) 一种具有腺苷受体拮抗活性的氨基嘧啶杂环化合物
EP2319842B1 (en) Fluorescent carbazole compounds for cancer diagnosis
WO2011041655A1 (en) Quinazolin-4-amine derivatives; and methods of use
CN110407806B (zh) 甲酰胺类化合物、其制备方法及其应用
CN113698357A (zh) 磺胺嘧啶类衍生物及其在抗肿瘤药物的应用
AU2014298433B2 (en) 2-benzoylaminobenzamide derivatives as Bcl-3 inhibitors
Zhou et al. Small molecules inhibit STAT3 activation, autophagy, and cancer cell anchorage-independent growth
CN113861130A (zh) 联苯磺胺噻二唑类衍生物及其在抗肿瘤药物的应用
WO2014071824A1 (zh) 4-氨基喹唑啉杂环化合物及其用途
CN109369620B (zh) 吡啶类化合物及其制备方法与抗胃癌应用
CN107903256B (zh) 一种含取代噻唑的2,4-二氨基嘧啶及其应用
CN110256465A (zh) 一种含二氢吡喃并噻唑的2,4-二氨基嘧啶及其应用
CN114920755B (zh) 具有黄酮母核的化合物及其在制备cdk1抑制剂中的用途
CN113563336B (zh) 一种含有吲哚醌单元的吴茱萸碱前药及其制备方法与应用
CN109776528A (zh) 一种2-(吲哚-3-基)-吡啶并咪唑及其应用
Li et al. A pomalidomide-based gefitinib PROTAC degrader effectively inhibits lung cancer progression in EGFR-TKIs-acquired resistant models by targeting EGFR degradation and ETFA-mediated ATP generation
KR100392468B1 (ko) 사이클린 의존 키나아제의 저해제로서 유용한3-히드록시크로멘-4-온 유도체
CN119874682B (zh) 一种1-甲基-6-氧基吲哚-2-甲酰胺衍生物、其制备方法及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20211126